These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 9425363)

  • 1. Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis.
    Thakur CP; Narain S; Kumar N; Hassan SM; Jha DK; Kumar A
    Ann Trop Med Parasitol; 1997 Sep; 91(6):611-6. PubMed ID: 9425363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate.
    Thakur CP; Thakur S; Narayan S; Sinha A
    Indian J Med Res; 2008 Jun; 127(6):582-8. PubMed ID: 18765878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
    Kumar D; Ramesh V; Verma S; Ramam M; Salotra P
    Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
    [No Abstract]   [Full Text] [Related]  

  • 4. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
    Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
    J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimony susceptible
    Ghosh S; Verma A; Kumar D; Deep DK; Ramesh V; Salotra P; Singh R
    Microbiol Spectr; 2024 Jun; 12(6):e0402623. PubMed ID: 38712926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis.
    Thakur CP; Narayan S
    Ann Trop Med Parasitol; 2004 Mar; 98(2):129-38. PubMed ID: 15035723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B and C viral infections in Indian kala-azar patients receiving injectable anti-leishmanial drugs: a community-based study.
    Singh S ; Kumar J; Singh R; Dwivedi SN
    Int J Infect Dis; 2000; 4(4):203-8. PubMed ID: 11231183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.
    Thakur CP; Kumar A; Mitra G; Thakur S; Sinha PK; Das P; Bhattacharya SK; Sinha A
    Indian J Med Res; 2008 Jul; 128(1):38-44. PubMed ID: 18820357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex.
    Sundar S; Murray HW
    J Infect Dis; 1996 Mar; 173(3):762-5. PubMed ID: 8627049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India.
    Thakur CP; Narayan S; Ranjan A
    Indian J Med Res; 2004 Sep; 120(3):166-72. PubMed ID: 15489554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar.
    Mishra M; Biswas UK; Jha AM; Khan AB
    Lancet; 1994 Dec; 344(8937):1599-600. PubMed ID: 7983993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.
    Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P
    J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone.
    Mukhopadhyay D; Mukherjee S; Ghosh S; Roy S; Saha B; Das NK; Chatterjee M
    Int J Dermatol; 2016 May; 55(5):e250-5. PubMed ID: 26536363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
    Karki P; Koirala S; Parija SC; Sethi M; Das ML
    Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
    Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
    J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
    Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
    J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar.
    Thakur CP; Sinha GP; Sharma V; Pandey AK; Kumar M; Verma BB
    Indian J Med Res; 1993 Jul; 97():170-5. PubMed ID: 8406644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
    Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
    Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-kala-azar dermal leishmaniasis with visceral leishmaniasis: a rare presentation.
    Rijal A; Agrawal S; Agarwalla A; Agrawal A; Rijal S
    Int J Dermatol; 2005 Jun; 44(6):494-6. PubMed ID: 15941439
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.